Raxibacumab Injection

None.

Infusion Reactions

Infusion-related reactions were reported during administration of raxibacumab in clinical trials including reports of rash, urticaria, and pruritus. If these reactions occur, slow or interrupt raxibacumab infusion and administer appropriate treatment based on severity of the reaction.

Premedicate with diphenhydramine within 1 hour prior to administering raxibacumab to reduce the risk of infusion reactions [see Dosage and Administration (2.1), Adverse Reactions (6.1)].

There is no clinical experience with overdosage of raxibacumab. In case of overdosage, monitor patients for any signs or symptoms of adverse effects.